A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer

INTRODUCTION: Abiraterone acetate and enzalutamide are commonly employed in prostate cancer therapy in an interchangeable manner. These drugs are highly efficacious in androgen antagonism to improve patient outcomes, but they also carry noteworthy risk of adverse effects. Common toxicities vary amon...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Yash B., Shaver, Amy L., Kelly, William Kevin, Lu-Yao, Grace
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423609/
https://www.ncbi.nlm.nih.gov/pubmed/36037225
http://dx.doi.org/10.1371/journal.pone.0273826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423609/
https://www.ncbi.nlm.nih.gov/pubmed/36037225
http://dx.doi.org/10.1371/journal.pone.0273826

Ejemplares similares